P.I.E. PHARMA LIMITED
Company number 03144078 · Monitor this company
This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.
Financial Health Assessment: P.I.E. PHARMA LIMITED
Company: P.I.E. Pharma Limited (Company number 03144078)
Status: Active, Private Limited Company
Latest detailed accounts reviewed: Year ended 31 March 2020 (filed under the small companies regime; the income statement was not delivered)
Filing status: Accounts and confirmation statement are up to date
1. Financial Health Score: C (Guarded)
Grade: C
Interpretation: The company is technically solvent and administratively compliant, but its financial resilience is weak. It resembles a patient with a stable heartbeat but very low blood pressure—able to function under normal conditions, yet vulnerable to any sudden shock. The score reflects a positive net asset position and timely filings, offset by critically low cash, a wafer-thin current ratio, and heavy reliance on intra-group funding.
2. Key Vital Signs
| Vital Sign | Latest Figure (2020) | What It Indicates |
|---|---|---|
| Cash at bank | £2,739 | Critically low. Cash covers less than one day of current liabilities. |
| Current ratio | 1.03 | Barely above 1.0. Current assets exceed current liabilities by only £100k, leaving almost no margin for error. |
| Working capital (net current assets) | £100,472 | Positive but narrow. It is almost entirely supported by amounts owed by group and connected companies. |
| Net assets / shareholders’ funds | £100,472 | Solvent on paper, but static. Equity has not grown meaningfully and remains close to the original share capital. |
| Retained earnings | £472 | Essentially zero. Profits are not being retained to build a financial cushion. |
| Intercompany debtor exposure | ~80% of total debtors | £2.7m of £3.4m debtors are owed by group undertakings or a connected company. The company’s liquidity depends on intra-group receipts. |
| Intercompany creditor exposure | ~91% of total creditors | £3.0m of £3.3m creditors is owed to group undertakings. External trade creditors are small by comparison. |
| Cash trend (2018–2020) | £665 → £792 → £2,739 | Weak but slightly improving; still dangerously thin. |
| Balance sheet scale | £10.3m (2018) → £3.4m (2019/2020) | Significant contraction in total assets and liabilities, consistent with a scaling back or group restructuring. |
| Statutory compliance | Up to date | Accounts and confirmation statement filed on time; audit opinion unqualified. |
Note: Because the income statement was not delivered under the small companies exemption, turnover-based ratios (such as profit margin or debtor days) cannot be calculated from the filed data.
3. Diagnosis
Condition: Fragile solvency with intercompany dependency and liquidity anemia
Symptoms analysis
The balance sheet is almost entirely current: the company holds no fixed assets, so it has no long-term asset base to fall back on if short-term funding dries up.
- Liquidity is critically weak. Cash of £2,739 against current liabilities of £3.3m means the company cannot meet its immediate obligations from its own resources. It is reliant on collecting intercompany debts to pay intercompany creditors.
- Working capital is circular. The £100,472 net current asset position is not generated from independent trading; it is the net of large intra-group balances. If a group undertaking delayed repayment or demanded repayment of the £3.0m owed to it, the company would likely be unable to pay its external creditors as they fall due.
- No internal profit reserve. The accounts show a profit for the year of £979,049, of which £979,000 was paid as dividends, leaving retained earnings at just £472. The company is distributing nearly all earnings rather than building a buffer.
- Contingent legal risk. The accounts state that proceedings were commenced in October 2019 concerning transactions from 2012, with the company defending a claim for equitable compensation. The financial effect is not estimable. The accounts state that the director does not consider the company’s financial position will be significantly affected, but this remains an unresolved contingent liability.
- Going concern reliance on group support. The accounts were prepared on a going concern basis, with the directors citing their own resources and governmental support (in the context of COVID-19) and acknowledging significant uncertainties.
Prognosis
Guarded. If group support continues and the legal claim resolves without a material outflow, the company can continue to trade as a going concern. However, its prognosis is stable only while the group umbrella remains intact. Any interruption to intercompany funding, an adverse legal outcome, or a sudden demand from external creditors could quickly push the company into liquidity distress. It lacks the financial reserves to absorb a shock independently.
4. Recommendations
- Build an internal cash buffer. Retain a portion of annual profits rather than distributing them in full. Even a modest retained-earnings reserve would improve the company’s ability to absorb unexpected costs or delays in intercompany receipts.
- Reduce intercompany dependency. Where practical, put formal repayment terms in place for amounts owed by group undertakings and connected companies, and seek to grow external trade debtor levels so the company is less reliant on intra-group cash flows.
- Secure independent liquidity. Arrange an overdraft or revolving credit facility from an external lender to reduce reliance on group funding and provide a safety net if intra-group balances are called in.
- Strengthen short-term cash-flow forecasting. Given the thin margin between current assets and current liabilities, prepare rolling weekly or monthly cash-flow forecasts to anticipate pressure points before they become critical.
- Monitor the legal claim closely. Obtain regular updates on the proceedings commenced in October 2019 and assess whether a contingent provision or earmarked reserve is prudent as more information becomes available.
- Maintain rigorous going-concern reviews. Because the accounts acknowledge significant uncertainties, the board should revisit going-concern assumptions at every reporting date and document the basis for continued reliance on group support.